Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alector

- PMLiVE

Biogen and Eisai revive abandoned aducanumab in shock turnaround

Companies plan to file the deserted Alzheimer’s drug with FDA

- PMLiVE

Avanir’s week goes from bad to worse with Alzheimer’s stumble

Suffers a blow as second phase 3 trial misses the mark

Detecting Alzheimer’s ahead of a cure

A focus on promising new research

- PMLiVE

A roadmap to the successful treatment of Alzheimer’s disease

Building on past research to learn more about the disease and how to treat it

What is changing in mental health and dementia care?

Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services

Wilmington Healthcare

- PMLiVE

GSK eyes follow-up HPV vaccine

Announces new alliance with Chinese pharma Innovax

- PMLiVE

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Latest BACE inhibitor to run into trouble

- PMLiVE

Bicycles Therapeutics enters dementia discovery with venture capital fund

Ambitious UK biotech expands research scope

- PMLiVE

Otsuka’s Alzheimer’s agitation drug hits the mark

Drug addresses one of the most challenging symptoms in dementia care

- PMLiVE

Undeterred by aducanumab failure, Eisai and Biogen plough on

Investors sceptical, though mechanism different

- PMLiVE

Where next in Alzheimer’s disease R&D?

How past failures and emerging biology are reshaping drug development

- PMLiVE

Biogen and Eisai pull plug on Alzheimer’s drug

Further undermines amyloid-targeting approach

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links